A

Agilent Technologies

$172.92

-0.60%
Nov 16, 2026
Bobby Quantitative Model
Agilent Technologies is a life sciences and diagnostics company, spun out of Hewlett-Packard in 1999, that sells analytical instruments, laboratory consumables, services, and diagnostic solutions across three segments: life sciences and diagnostics, Agilent CrossLab (consumables and services), and applied markets. It is a scaled, high-touch incumbent rather than a disruptor, with a moat built on instrument installed-base lock-in, recurring service and consumable revenue, and deep relationships in biopharma, chemical, and advanced materials end markets that management characterizes as its stickiest. The current investor narrative centers on a sharp operational rebound: a strong quarterly beat and raised full-year profit forecast in late May drove a step-change in the share price, and the story has since broadened to include margin expansion, the strategic Biocare Medical acquisition to deepen pathology exposure, and the durability of China and biopharma demand. Debate now hinges on whether the recent earnings momentum and margin recovery are structural or cyclical, and whether the stock's re-rating has run ahead of the underlying growth rate.

People also watch

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMO

Analysis
Danaher Corporation

Danaher Corporation

DHR

Analysis
Natera

Natera

NTRA

Analysis
IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXX

Analysis
Waters Corporation

Waters Corporation

WAT

Analysis

BobbyInvestment Opinion: Should I buy A Today?

Rating: Hold, with a constructive bias toward accumulating on weakness. The core thesis is that Agilent's operational rebound is real — gross margin up roughly 370bps year-over-year to 55.48%, revenue growth accelerating to 8.06%, and $1.267 billion of TTM free cash flow — but the 55.74% six-month re-rating has already captured most of that improvement, leaving only 4.7% upside to the $182.05 average analyst target despite a unanimous-leaning consensus of 15 Buy, 7 Hold, and zero Sell ratings (recommendation mean 1.77).

The supporting evidence is genuinely strong on fundamentals: forward PE of 25.89x against trailing 31.89x implies the market already discounts the consensus $9.10 EPS, and the 6.0-point gap between those multiples confirms earnings growth is expected rather than hoped for. Revenue has climbed sequentially every quarter from $1.681 billion in Q1 2025 to $1.878 billion in Q3 2026, net margin expanded from 16.96% in Q1 2026 to 19.28%, operating margin reached 23.64%, and Q3 free cash flow of $439 million on just $80 million of capex funded a $950 million Biocare acquisition plus $72 million of dividends and $78 million of buybacks while debt-to-equity stayed at 0.50. The offsetting data points are the PEG ratio of 9.44, price-to-book of 6.14x, and EV/EBITDA of 23.43x, which together mark this as a premium compounder with little valuation cushion.

The biggest risks that could invalidate the thesis are a rollback in gross margin toward the 51.80% level seen in Q4 2025, a biopharma R&D funding slowdown or renewed China weakness given that over half of sales come from biopharma, chemical, and advanced materials end markets, and Biocare integration disappointment. This Hold would upgrade to Buy if the stock pulled back toward the $155-$160 zone (near the analyst low target, implying a forward PE closer to 17-18x on $9.10 EPS) or if gross margin held above 55% for two more quarters with revenue growth reaccelerating above 9%; it would downgrade to Sell if gross margin fell below 53% or if forward EPS estimates were cut below $8.90. On balance the stock is fairly valued to modestly overvalued relative to its own history — 31.89x trailing sits above the 23.9x-27.0x band of 2025 — so the verdict is quality at a full price, not a bargain.

Sign up to view all

A 12-Month Price Forecast

Agilent is a high-quality, cash-generative life-science tools franchise whose margin recovery and 8% revenue growth are well supported by $1.267 billion of TTM free cash flow and a 0.50 debt-to-equity ratio, but the stock has already re-rated 55.74% in six months and now trades at 25.89x forward earnings against a 9.44 PEG. The analyst consensus of Buy with a $182.05 average target implies only 4.7% upside, and the wide $155-$200 range shows the debate is about multiple durability, not earnings. I would upgrade to bullish if gross margin held above 55% for two more quarters with revenue growth reaccelerating above 9%, or if the stock pulled back toward $155-$160 to restore valuation cushion. I would downgrade to bearish if gross margin slipped below 53%, forward EPS estimates were cut below $8.90, or biopharma and China demand visibly deteriorated.

Historical Price
Current Price $172.92
Average Target $180.00
High Target $200.00
Low Target $155.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Agilent Technologies's 12-month outlook, with a consensus price target around $182.05 and implied upside of +5.3% versus the current price.

Average Target

$182.05

22 analysts

Implied Upside

+5.3%

vs. current price

Analyst Count

22

covering this stock

Price Range

$155 - $200

Analyst target range

Buy
15 (68%)
Hold
7 (32%)
Sell
0 (0%)

Coverage is deep and overwhelmingly constructive: 20 analysts cover Agilent with 15 Buy ratings, 7 Hold ratings, and zero Sells, yielding a consensus recommendation of "buy" and a recommendation mean of 1.77 (where 1.0 is a strong buy). The average target price of $182.05 implies roughly 4.7% upside from the current $173.96, a modest gap that suggests the stock has largely caught up to consensus after its 55.74% six-month run. The bullish tilt is reinforced by recent institutional activity, with Morgan Stanley, TD Cowen, Barclays, Wells Fargo, Goldman Sachs, JP Morgan, Bernstein, Stifel, and B of A all reiterating Overweight, Buy, or Outperform ratings in August and October 2026, indicating stable rather than fading conviction. The target range of $155.00 to $200.00 is moderately wide, spanning about 26% from low to high, which signals meaningful dispersion in assumptions about the durability of the margin recovery and growth trajectory. The $200 high target likely assumes continued earnings beats, multiple expansion toward the upper end of the historical PE band, and successful integration of the Biocare pathology acquisition, while the $155 low target appears to price in a slowdown in biopharma and China demand, margin compression, or a de-rating toward the lower end of the historical multiple range. With consensus EPS estimates clustered tightly between $8.91 and $9.43 (average $9.10) and revenue estimates between $9.20 billion and $9.54 billion (average $9.37 billion), the fundamental forecasts are relatively aligned, meaning the wide price-target spread is driven more by multiple assumptions than by earnings disagreement; the absence of any Sell ratings and the steady stream of reiterations point to strong institutional conviction, though the limited implied upside argues for patience on entry rather than chasing the stock near its 52-week high.

Drowning in data?

Find the real signal!

Bulls vs Bears: A Investment Factors

The bull case currently has stronger evidence: margins are expanding materially (gross margin up ~370bps year-over-year to 55.48%), revenue is accelerating sequentially to 8.06% growth, free cash flow of $1.267 billion comfortably funds M&A and shareholder returns, and 15 of 20 analysts rate Buy with zero Sells. The bear case rests less on fundamentals than on price: at 25.89x forward earnings with a 9.44 PEG and only 4.7% implied upside to the $182.05 average target, the stock has already priced in much of the recovery after a 55.74% six-month run. The single most important tension is whether the margin recovery is structural (mix shift toward high-margin CrossLab services and consumables) or cyclical (a rebound off a depressed 2025 base) — if structural, the premium multiple is justified; if cyclical, the stock is vulnerable to a de-rating toward the $155 low target. Secondary tension centers on biopharma and China demand durability and Biocare integration, which drive the wide $155-$200 target dispersion.

Bullish

  • Margin expansion is the standout story: Gross margin climbed from 51.80% in Q4 2025 to 55.48% in Q3 2026, and net margin rose from 16.96% in Q1 2026 to 19.28% in the latest quarter. Operating margin reached 23.64%, up from 20.71% in Q3 2025, demonstrating genuine operating leverage rather than one-off cost cuts.
  • Recurring revenue ballast from CrossLab: Agilent CrossLab generated $786 million of the $1.878 billion in Q3 2026 revenue, making consumables and services the largest and most stable segment. This installed-base lock-in supports pricing power and explains why gross margins can expand even as instrument demand fluctuates.
  • Revenue growth accelerating sequentially: Q3 2026 revenue of $1.878 billion grew 8.06% year-over-year and rose sequentially from $1.798 billion in Q1 and $1.835 billion in Q2. The multi-quarter climb from $1.681 billion in Q1 2025 confirms a durable mid-single-digit-plus growth trajectory rather than a single-quarter bounce.
  • Strong cash generation funds growth and returns: TTM free cash flow is $1.267 billion, with Q3 2026 FCF of $439 million on just $80 million of capex. That cash funded a $950 million Biocare acquisition plus $72 million of dividends and $78 million of buybacks in the quarter, all while debt-to-equity stayed at a modest 0.50.

Bearish

  • Valuation leaves little room for error: At 31.89x trailing and 25.89x forward earnings, the stock sits in the upper-middle of its multi-year PE band (above the 23.9x-27.0x range in 2025). The PEG ratio of 9.44 flags that investors are paying a rich price relative to the growth rate.
  • Re-rating has run ahead of fundamentals: The stock is up 55.74% over six months and 26.10% year-to-date, yet consensus revenue growth is only about 8% and the average analyst target implies just 4.7% upside. Much of the move reflects multiple expansion rather than earnings revisions.
  • Momentum is decelerating near the high: The 1-month change is -2.3% versus a 3-month gain of 17.12%, and at $173.96 the stock sits at roughly 88% of its 52-week range, just 5.2% below the $182.99 high. This consolidation after a parabolic run from ~$112 in mid-May raises the risk of profit-taking.
  • Elevated volatility amplifies drawdowns: Beta of 1.237 means Agilent is roughly 24% more volatile than the market, and the historical max drawdown of -29.87% shows how sharply the name can correct. A sentiment shift could quickly erase a large portion of the six-month gain.

A Technical Analysis

Agilent is in a powerful, sustained uptrend: the stock is up 18.43% over the past year and 26.10% year-to-date, and at $173.96 it sits at roughly 88% of its 52-week range of $108.35 to $182.99, just 5.2% below the high. That positioning signals momentum leadership rather than a value opportunity, and the 55.74% six-month gain confirms the move has been driven by a re-rating rather than a slow grind. The stock is not overextended relative to its own high, but it is clearly in the upper quartile of its range, where incremental buyers are paying up for continued execution. Recent momentum is decelerating even as the longer-term trend remains intact: the 1-month change is -2.3% versus a 3-month gain of 17.12%, a classic consolidation after a parabolic run from roughly $112 in mid-May to $181 in late October. Notably, this modest pullback occurred while the S&P 500 fell 2.26% over the same month, giving Agilent a positive 2.24% relative-strength spread and suggesting the weakness is profit-taking rather than distribution. The 3-month relative strength of +19.95 points and 6-month relative strength of +53.61 points versus SPY underscore how decisively the stock has outperformed; with no RSI or volume data provided, the divergence between flat 1-month and strong 3-month performance is the key signal to monitor for a trend reversal. Key levels are well defined: support sits at the 52-week low of $108.35, with nearer-term support implied by the September consolidation around $143-$147, while resistance is the 52-week high of $182.99, just above the recent $181.48 peak. A breakout above $183 would confirm the uptrend's next leg and likely trigger momentum-driven buying, whereas a breakdown below $143 would break the pattern of higher lows and flag a deeper mean-reversion move toward the $108 area. With a beta of 1.237, Agilent is roughly 24% more volatile than the market, meaning position sizing should account for amplified drawdowns; the historical max drawdown of -29.87% is a useful reminder of how sharply this name can correct when sentiment shifts.

Beta

1.24

1.24x market volatility

Max Drawdown

-29.9%

Largest decline past year

52-Week Range

$108-$183

Price range past year

Annual Return

+17.8%

Cumulative gain past year

PeriodA ReturnS&P 500
1m-0.0%-3.0%
3m+16.5%-3.6%
6m+52.0%-0.2%
1y+17.8%+10.1%
ytd+25.3%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

A Fundamental Analysis

Revenue is growing at a healthy, accelerating clip: fiscal Q3 2026 (quarter ended July 31, 2026) revenue was $1.878 billion, up 8.06% year-over-year from $1.738 billion, and up sequentially from $1.798 billion in Q1 and $1.835 billion in Q2. The multi-quarter trend is clearly positive, with quarterly revenue rising from $1.681 billion in Q1 2025 to the latest $1.878 billion, and segment data shows Agilent CrossLab at $786 million, Life Sciences and Applied Markets at $746 million, and Applied Markets at $346 million, indicating that recurring consumables and services remain the largest and most stable contributor. This trajectory supports the investment case for a durable, mid-single-digit-plus grower with recurring revenue ballast rather than a cyclical instrument vendor. Profitability is robust and expanding: Q3 2026 net income was $362 million on a 19.28% net margin, with gross margin of 55.48%, up from 52.59% in Q3 2025 and 54.99% in Q2 2026, while operating margin reached 23.64%. The margin progression is the standout fundamental story, with gross margin climbing from 51.80% in Q4 2025 to 55.48% in the latest quarter and net margin rising from 16.96% in Q1 2026 to 19.28%, reflecting operating leverage and a favorable mix toward higher-margin services and consumables. These margins are consistent with a premium life-science tools franchise and suggest the company has pricing power and cost discipline. The balance sheet is solid and cash-generative: debt-to-equity is a modest 0.50, the current ratio is 1.96, and TTM free cash flow is $1.267 billion, with Q3 2026 free cash flow of $439 million on operating cash flow of $519 million against capex of just $80 million. ROE of 19.33% and ROA of 8.63% confirm efficient capital deployment, and the company returned cash via $72 million in dividends and $78 million in buybacks in the quarter while funding a $950 million acquisition, demonstrating internal cash generation sufficient to support both growth investment and shareholder returns without straining leverage.

Quarterly Revenue

$1.9B

2026-07

Revenue YoY Growth

+8.1%

YoY Comparison

Gross Margin

55.5%

Latest Quarter

Free Cash Flow

$1.3B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Agilent CrossLab
Applied Markets
Life Sciences and Applied Markets

Open an Account, get $2 TSLA now!

Valuation Analysis: Is A Overvalued?

Because Agilent is solidly profitable (Q3 2026 net income of $362 million), the PE ratio is the appropriate primary metric: the stock trades at 31.89x trailing earnings and 25.89x forward earnings, and the 6.0-point gap between the two implies the market expects meaningful EPS growth, consistent with the consensus estimate of $9.10 for the forward period. The forward multiple of 25.89x is the more decision-relevant figure, as it prices in the earnings recovery already underway. Relative to its own history, the current 31.89x trailing PE sits above the 23.9x-27.0x range seen through 2025 and well above the 15.9x trough in late 2023, but below the 35.9x-36.4x peaks in 2025, placing it in the upper-middle of its multi-year band. On price-to-sales, the stock at 5.96x is actually below the 17.8x-22.3x historical PS readings recorded in the ratios data, a discrepancy that likely reflects a change in share count or data methodology and should be treated cautiously; the more reliable signals are the PE and EV/EBITDA of 23.43x. The PEG ratio of 9.44 is elevated and flags that the market is paying a rich price relative to the growth rate, while the 6.14x price-to-book and 26.57x price-to-cash-flow reinforce that this is a premium-multiple compounder rather than a value stock. Peer industry averages were not provided in the valuation data, so a direct sector spread cannot be quantified; however, a 25.89x forward PE for a high-quality, mid-single-digit grower with 55% gross margins and 19% net margins is broadly in line with premium life-science tools peers and leaves limited room for execution missteps.

PE

31.9x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 24x~37x

vs. Industry Avg

35.2x

Industry PE ~35.2x*

EV/EBITDA

23.4x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks are moderate but real. The company carries debt-to-equity of 0.50 and interest expense of $29 million per quarter, and the $950 million Biocare acquisition adds integration and goodwill risk on top of an already premium 6.14x price-to-book. Earnings quality depends on continued margin expansion — gross margin must hold near 55.48% and net margin near 19.28%, because at 25.89x forward earnings, any reversal toward the 51.80% gross margin seen in Q4 2025 would compress EPS and trigger multiple contraction simultaneously. Revenue concentration is another vulnerability: over half of sales come from biopharma, chemical, and advanced materials end markets, and China is one of the two largest country concentrations, so a funding slowdown in biopharma R&D or renewed China weakness would hit the top line directly. Finally, the PEG ratio of 9.44 means the valuation depends on delivering the consensus $9.10 EPS; a miss would be punished disproportionately. Market and competitive risks center on valuation compression. At 31.89x trailing and 25.89x forward earnings, the stock trades in the upper-middle of its historical band and well above the 15.9x trough of late 2023, leaving limited cushion if growth normalizes toward the high-single digits. Beta of 1.237 means roughly 24% more volatility than the market, so a hawkish Fed or sector rotation out of premium healthcare compounders would hit Agilent harder than the index — the recent news flow already notes sticky inflation keeping the Fed hawkish and pressuring non-AI sectors. Competitive disruption in analytical instruments and diagnostics, plus regulatory and reimbursement risk in the pathology market Agilent is entering via Biocare, add external uncertainty. The stock's 55.74% six-month gain also makes it a natural source of funds if momentum reverses. The worst-case scenario is a chain in which biopharma and China demand decelerate, gross margin rolls back toward the low-52% range, Biocare integration disappoints, and the market de-rates the multiple toward the low end of its historical band — a combination that would push the stock toward the $155 analyst low target, roughly -10.9% from $173.96. A deeper sentiment-driven correction toward the September consolidation zone of $143-$147 would imply about -15% to -18%, and a full mean-reversion move to the 52-week low of $108.35 would represent roughly -37.7%. Given the historical max drawdown of -29.87%, investors should size positions for a realistic 15-30% drawdown rather than the modest 4.7% implied upside to consensus.

FAQ

Ranked by severity: first, valuation compression — at 31.89x trailing and 25.89x forward earnings with a 9.44 PEG, any growth normalization toward the high-single digits could de-rate the multiple toward the $155 analyst low target, about -10.9%. Second, margin reversal — gross margin must hold near 55.48%; a rollback toward the 51.80% Q4 2025 level would compress EPS and the multiple simultaneously. Third, end-market concentration — over half of sales come from biopharma, chemical, and advanced materials, and China is a major country concentration, so an R&D funding slowdown or renewed China weakness hits the top line directly. Fourth, integration and volatility — the $950 million Biocare deal carries goodwill and execution risk, while a beta of 1.237 and a historical max drawdown of -29.87% mean market selloffs are amplified; the 52-week low of $108.35 is roughly -37.7% from here.

The 12-month scenario framework assigns 55% to a base case of $175-$185, 25% to a bull case of $190-$200, and 20% to a bear case of $155-$165. The base case assumes revenue growth holds in the 7-9% range consistent with the 8.06% Q3 2026 print, gross margin stays between 54% and 56%, and the forward PE holds near 25.89x, converging on the $182.05 average target. The bull case requires gross margin above 55.5% for a second consecutive quarter plus Biocare contribution ahead of plan, driving EPS toward the $9.43 high estimate and a re-rating to the $200 high target. The bear case assumes biopharma and China weakness plus margin rollback toward the low-52% range, pulling the stock to the $155 low target. The base case is most likely, and its key assumption is margin durability.

Agilent screens as fairly valued to modestly overvalued. The stock trades at 31.89x trailing and 25.89x forward earnings, with the 6.0-point gap implying the market already discounts the consensus $9.10 forward EPS. Relative to its own history, 31.89x trailing sits above the 23.9x-27.0x band seen through 2025 and far above the 15.9x trough in late 2023, though below the 35.9x-36.4x peaks. Supporting premium-multiple metrics include a 6.14x price-to-book, 23.43x EV/EBITDA, 26.57x price-to-cash-flow, and a 9.44 PEG that flags a rich price relative to growth. The market is paying for a durable mid-single-digit-plus grower with 55% gross margins and 19% net margins, but at 25.89x forward there is minimal room for execution missteps — a de-rating toward the low end of the historical band is the main valuation risk.

From a risk/reward standpoint the setup is balanced rather than compelling: at $173.96 the stock offers only about 4.7% upside to the $182.05 average analyst target, while the bear case toward the $155 low target implies roughly -10.9% and a full retrace to the $108.35 52-week low would be about -37.7%. The fundamental case is genuinely strong — gross margin of 55.48% in Q3 2026 versus 51.80% in Q4 2025, revenue growth of 8.06%, and $1.267 billion of TTM free cash flow — and 15 of 20 analysts rate Buy with zero Sells. But the 55.74% six-month gain has already captured much of that improvement, leaving a 25.89x forward PE and a 9.44 PEG with little cushion. It is a reasonable buy for patient, long-horizon investors who can tolerate a 15-30% drawdown, and a better buy on a pullback toward $155-$160 where the forward multiple would compress toward 17-18x on $9.10 EPS.

Agilent is better suited to long-term holding than short-term trading. It is a mature, cash-generative franchise — $1.267 billion of TTM free cash flow, 19.33% ROE, a 0.50 debt-to-equity ratio, and a small 0.68% dividend at a 21.6% payout ratio — with recurring CrossLab consumables and services revenue providing earnings visibility. That profile rewards patience, but the beta of 1.237 and historical max drawdown of -29.87% mean short-term traders face amplified volatility, and the recent 1-month change of -2.3% after a 55.74% six-month run suggests momentum is consolidating. A minimum holding period of 18-24 months is appropriate to ride through a full earnings cycle and Biocare integration, with position sizing that anticipates a 15-30% drawdown. Short-term traders should wait for either a confirmed breakout above $182.99 or a pullback toward the $143-$147 support zone before entering.